Mutually reinforcing effects of genetic variants and interferon‐β 1a therapy for pulmonary arterial hypertension development in multiple sclerosis patients

Based on a small number of cases, interferon beta (IFN‐β) has been added to the list of drugs that might induce pulmonary arterial hypertension (PAH) in the current European guidelines for the diagnosis and treatment of pulmonary hypertension. Here, we propose that multiple sclerosis patients who are genetically predisposed to PAH may be at higher risk to develop disease when treated with IFN‐β. We included two patients with multiple sclerosis...